Citi Names Zoetis as Top Pick: Could Pet Economy Growth Be the Best Trade for 2026?

Citi has elevated Zoetis to its top position with a 'Buy' rating, highlighting the company as the most attractive investment target for 2026. The analysts' report emphasized the positive impact that rapid growth in the pet sector is expected to have on Zoetis's product portfolio and market share. Zoetis is a global leader in animal health, serving a broad customer base with veterinary medicines, vaccines, and animal care products. According to Citi's assessment, the company's recent profit margins and revenue growth are progressing in line with industry growth trends. In this context, the company's growth forecasts, competitive advantage in the sector, and strong R&D investments form the basis of the buy recommendation. Market analysts have highlighted Zoetis's potential to benefit from increasing consumer demand for pet care. In particular, the tendency of pet owners to invest more in health and wellness issues presents a growth opportunity that aligns with the company's strategy to expand its product portfolio. Considering these dynamics, Citi predicts that Zoetis's stock could experience significant value appreciation by 2026. For investors, Citi's buy recommendation offers an opportunity to formulate a long-term investment strategy, taking into account Zoetis's current market position and growth potential. However, given market fluctuations and sectoral risks, it is advised that investment decisions be carefully evaluated. Not investment advice.